Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Beaumont

Showing results (341-350 of 368) with videos related to

Pageof 37
Sort By:
Journal of the American Chemical Society|January 2, 2008
Quantifying weak hydrogen bonding in uracil and 4-cyano-4'-ethynylbiphenyl: a combined computational and experimental investigation of NMR chemical shifts in the solid stateAnne-Christine Uldry, John M Griffin, Jonathan R Yates, et al.
American Journal of Neurodegenerative Disease|January 29, 2015
Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's diseaseJoan Hq Shen, Qi Shen, Holly Yu, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 9, 2019
Does recall period matter? Comparing PROMIS<sup>®</sup> physical function with no recall, 24-hr recall, and 7-day recallDavid M Condon, Robert Chapman, Sara Shaunfield, et al.
Autism Research : Official Journal of the International Society for Autism Research|August 26, 2020
Neural Responses to a Putative Set-shifting Task in Children with Autism Spectrum DisorderBryce Dirks, Celia Romero, Willa Voorhies, et al.
Journal of Pain and Symptom Management|July 18, 2009
Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapyBarbara A Murphy, Jennifer L Beaumont, John Isitt, et al.
Journal of Clinical Epidemiology|March 9, 2016
PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditionsKaron F Cook, Sally E Jensen, Benjamin D Schalet, et al.
Neurology|March 13, 2013
Norming plans for the NIH ToolboxJennifer L Beaumont, Richard Havlik, Karon F Cook, et al.
Annals of the American Thoracic Society|September 24, 2020
Evaluating the Minimal Clinically Important Difference of the King's Sarcoidosis Questionnaire in a Multicenter Prospective StudyRobert P Baughman, Marc A Judson, Jennifer L Beaumont, et al.
Respiratory Medicine|March 31, 2022
The association of baseline sarcoidosis measurements with 6-month outcomes that are of interest to patients: Results from the On-line Sarcoidosis Assessment Platform Study (OSAP)Marc A Judson, Recai Yucel, Sara Preston, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 1, 2011
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancerThomas E Stinchcombe, Amy H Peterman, Carrie B Lee, et al.
Pageof 37

Showing results (341-350 of 368) with videos related to

Sort By:
Pageof 37
Journal of the American Chemical Society|January 2, 2008
Quantifying weak hydrogen bonding in uracil and 4-cyano-4'-ethynylbiphenyl: a combined computational and experimental investigation of NMR chemical shifts in the solid stateAnne-Christine Uldry, John M Griffin, Jonathan R Yates, et al.
American Journal of Neurodegenerative Disease|January 29, 2015
Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's diseaseJoan Hq Shen, Qi Shen, Holly Yu, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 9, 2019
Does recall period matter? Comparing PROMIS<sup>®</sup> physical function with no recall, 24-hr recall, and 7-day recallDavid M Condon, Robert Chapman, Sara Shaunfield, et al.
Autism Research : Official Journal of the International Society for Autism Research|August 26, 2020
Neural Responses to a Putative Set-shifting Task in Children with Autism Spectrum DisorderBryce Dirks, Celia Romero, Willa Voorhies, et al.
Journal of Pain and Symptom Management|July 18, 2009
Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapyBarbara A Murphy, Jennifer L Beaumont, John Isitt, et al.
Journal of Clinical Epidemiology|March 9, 2016
PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditionsKaron F Cook, Sally E Jensen, Benjamin D Schalet, et al.
Neurology|March 13, 2013
Norming plans for the NIH ToolboxJennifer L Beaumont, Richard Havlik, Karon F Cook, et al.
Annals of the American Thoracic Society|September 24, 2020
Evaluating the Minimal Clinically Important Difference of the King's Sarcoidosis Questionnaire in a Multicenter Prospective StudyRobert P Baughman, Marc A Judson, Jennifer L Beaumont, et al.
Respiratory Medicine|March 31, 2022
The association of baseline sarcoidosis measurements with 6-month outcomes that are of interest to patients: Results from the On-line Sarcoidosis Assessment Platform Study (OSAP)Marc A Judson, Recai Yucel, Sara Preston, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 1, 2011
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancerThomas E Stinchcombe, Amy H Peterman, Carrie B Lee, et al.
Pageof 37